Xarelto Cases Consolidated in New Orleans
This is Michael Brady Lynch, lead trial attorney for The Michael Brady Lynch Firm.
The most important recent news is that a federal panel of judges has granted the request of The Michael Brady Lynch Firm and others to centralize pending and subsequent Xarelto lawsuits. The judge will centralize these Xarelto case in the U.S. District Court for the Eastern District of Louisiana. These will combine into a Multi-District Litigation (MDL). Such coordinated proceedings are common in complex pharmaceutical litigation, where a large number of lawsuits have been brought involving similar injuries associated with the same medication or product.
The U.S. Judicial Panel On Multidistrict Litigation (JPML) issued an order on December 12, 2014, to transfer over 50 Xarelto cases to the Louisiana court for consolidation under U.S. District Judge Eldon E. Fallon. Also, this is a very good development and will help streamline the progress of Xarelto cases nationwide.
Judge Fallon is no stranger to overseeing complex national pharmaceutical mass torts. Judge Fallon oversaw the Vioxx MDL. This resulted in defendant Merck setting up a $4.85 billion settlement fund to pay nearly 35,000 complaints.
The Michael Brady Lynch Firm continues to be one of the leaders in Xarelto litigation nationwide. Our firm has filed in excess of 35 cases in both state and federal court.
Background on Xarelto Bleeding Problems
Xarelto (rivaroxoaban) was introduced by Bayer and Johnson & Johnson’s Janssen Pharmaceuticals in 2011, as part of a new generation of anticoagulants promoted as a superior alternative to Coumadin (warfarin), which has been the go-to blood thinner for prevention of strokes among patients with atrial fibrillation for decades.
While all blood thinners carry a risk of bleeding problems, Xarelto and other members of this new generation of anticoagulants lack an approved antidote. Doctors use the antidote to reverse the effects of the drug. While doctors can quickly stop the blood thinning effects of warfarin, users of Xarelto have reported experiencing uncontrollable bleeding. Physicians were unable to stop it. Therefore the bleeding led to severe injury or death.
According to allegations raised in the mounting Xarelto litigation over bleeding problems, Bayer and Johnson & Johnson placed their desire for profits before consumer safety by failing to adequately warn about the risks associated with their new medication or the lack of an available Xarelto reversal agent.
Therefore, if you or a loved were prescribed Xarelto and suffered an internal bleed or intracranial hemorrhage, please contact The Michael Brady Lynch Firm. We offer a free, no-obligation case evaluation.
The Michael Brady Lynch Firm is a trial firm. We have a focus on pharmaceutical mass tort cases involving SSRI and Anti-Seizure Medication Birth Defects. This includes Lexapro, Zoloft, Effexor, Prozac, Celexa, Paxil, Depakote, and Topamax. We also try Testosterone cardiac events, Mirena IUD, Actos Bladder Cancer, and Lipitor diabetes cases. In addition to trying medical device cases including DePuy Hip and Trans-Vaginal Mesh cases. Contact us today if you or someone you know has experienced side effects involving these products.